Home > Oncology > Eosinophil count tied to immunotherapy’s efficacy, adverse effects in lung cancer

Eosinophil count tied to immunotherapy’s efficacy, adverse effects in lung cancer

Journal
Lung Cancer
Reuters Health - 08/09/2020 - In patients with advanced non-small-cell lung cancer receiving immune-checkpoint inhibitors (ICIs), baseline peripheral-blood absolute eosinophil count (AEC) is tied to both ICI-related pneumonitis and better clinical outcome, according to researchers in China. As Dr. Chunxia Su explained in an email to Reuters Health, "Predictive markers of efficacy of immunotherapy are often closely related to the occurrence of adverse reactions." In a paper in Lung Cancer, Dr. Su of Tongji University School of Medicine, in Shanghai, and colleagues note that treatment with ICIs is accompanied by a wide range of immune-related adverse events (irAEs). Among the most worrisome of these is ICI-pneumonitis. ICI-pneumonitis presents as the development of respiratory signs and symptoms, including cough, dyspnea and hypoxia, along with the presence of new pulmonary infiltrates on chest CT scans after initiation of ICI treatment. To help establis...


Please login to read the full text of the article.


If you have no account yet, please register now.





Posted on